REPLIGEN CORP SEC 10-Q Report
Repligen Corp, a leading provider of advanced bioprocessing technologies and solutions, has released its Form 10-Q report for the second quarter of 2025. The report highlights significant growth in both financial and operational metrics, driven by robust performance across its key franchises and strategic acquisitions.
Financial Highlights
Total Revenue: Repligen reported total revenue of $182.4 million for Q2 2025, marking a 14.8% increase compared to Q2 2024. For the first half of 2025, total revenue reached $351.5 million, up 12.7% from the same period in 2024. This growth was primarily driven by the Chromatography and Analytics franchises.
Gross Profit: The company achieved a gross profit of $91.1 million for Q2 2025, reflecting a gross margin of 50.0%. For the first half of 2025, gross profit was $181.9 million, with a gross margin of 51.7%. The improved margins were influenced by a favorable product mix and reduced material costs.
Income from Operations: Income from operations for Q2 2025 was $13.9 million, a significant increase from $5.5 million in Q2 2024. For the first half of 2025, income from operations rose to $20.5 million, compared to $9.2 million in the first half of 2024, driven by higher revenue and effective cost management.
Net Income: Net income for Q2 2025 was $14.9 million, up from $5.7 million in Q2 2024. For the first half of 2025, net income increased to $20.7 million from $9.0 million in the same period of the previous year, reflecting strong operational performance.
Basic and Diluted EPS: Basic and diluted earnings per share (EPS) for Q2 2025 were $0.26, compared to $0.10 for Q2 2024, indicating improved profitability.
Business Highlights
Revenue Segments: The company's revenue growth in Q2 2025 was driven by its Chromatography and Analytics franchises. For the first half of the year, the Proteins, Chromatography, and Analytics franchises were the primary contributors to revenue growth.
Geographical Performance: Revenue distribution remained consistent across regions, with North America contributing 49%, Europe 36%, and APAC/Other 15% of total revenue for the six months ended June 30, 2025. This reflects stable performance across all major markets.
New Product Launches: Repligen completed the acquisition of 908 Devices Inc.'s desktop portfolio for bioprocessing process analytical technology applications on March 4, 2025. This acquisition is expected to enhance the company's product offerings in the bioprocessing analytics space.
New Production Facilities: The acquisition of facilities in North Carolina and Braunschweig, Germany, as part of the 908 Devices PAT Portfolio acquisition, indicates an expansion in production capabilities to support the new product lines.
Future Outlook: Repligen anticipates continued growth in its bioprocessing business, driven by the integration of recent acquisitions and ongoing demand for its innovative technologies in the production of biologic drugs. The company is also monitoring macroeconomic trends, including foreign exchange fluctuations and supply chain challenges, which could impact future operations.
SEC Filing: REPLIGEN CORP [ RGEN ] - 10-Q - Aug. 07, 2025